JP2007513072A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513072A5
JP2007513072A5 JP2006538539A JP2006538539A JP2007513072A5 JP 2007513072 A5 JP2007513072 A5 JP 2007513072A5 JP 2006538539 A JP2006538539 A JP 2006538539A JP 2006538539 A JP2006538539 A JP 2006538539A JP 2007513072 A5 JP2007513072 A5 JP 2007513072A5
Authority
JP
Japan
Prior art keywords
medicament
antibody
cell
medicament according
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513072A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/037137 external-priority patent/WO2005044998A2/en
Publication of JP2007513072A publication Critical patent/JP2007513072A/ja
Publication of JP2007513072A5 publication Critical patent/JP2007513072A5/ja
Pending legal-status Critical Current

Links

JP2006538539A 2003-11-05 2004-11-05 Ｃｄｉｍ結合抗体における増強されたｂ細胞細胞傷害性 Pending JP2007513072A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51777503P 2003-11-05 2003-11-05
PCT/US2004/037137 WO2005044998A2 (en) 2003-11-05 2004-11-05 Enhanced b cell cytotoxicity of cdim binding antibody

Publications (2)

Publication Number Publication Date
JP2007513072A JP2007513072A (ja) 2007-05-24
JP2007513072A5 true JP2007513072A5 (https=) 2007-12-20

Family

ID=34572964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538539A Pending JP2007513072A (ja) 2003-11-05 2004-11-05 Ｃｄｉｍ結合抗体における増強されたｂ細胞細胞傷害性

Country Status (12)

Country Link
US (1) US20050112130A1 (https=)
EP (1) EP1682179A4 (https=)
JP (1) JP2007513072A (https=)
CN (1) CN1878568A (https=)
AU (1) AU2004288231A1 (https=)
BR (1) BRPI0416243A (https=)
CA (1) CA2542886A1 (https=)
IL (1) IL175318A0 (https=)
MX (1) MXPA06005104A (https=)
SG (1) SG148161A1 (https=)
WO (1) WO2005044998A2 (https=)
ZA (1) ZA200603563B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
KR20020027490A (ko) * 1999-07-12 2002-04-13 제넨테크, 인크. Ｃｄ20에 결합하는 길항제를 사용한 외래 항원에 대한면역 반응 차단 방법
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
US7577655B2 (en) * 2003-09-16 2009-08-18 Google Inc. Systems and methods for improving the ranking of news articles
NZ584288A (en) * 2004-02-06 2011-10-28 Elan Pharm Inc Methods and compositions for treating tumors and metastatic disease
DK1814913T3 (en) 2004-11-05 2015-09-28 Univ Leland Stanford Junior ANTIBODY-INDUCED CELL membrane damage.
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US8293716B2 (en) * 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
WO2007030602A2 (en) * 2005-09-07 2007-03-15 The University Of Iowa Research Foundation Treatment of b cells with il-21 and b cell activators induces granzyme b production
US20070081989A1 (en) * 2005-09-19 2007-04-12 Sanders Martin E Treatment of B cell diseases using anti-germline antibody binding agents
WO2007059099A2 (en) * 2005-11-14 2007-05-24 Point Therapeutics, Inc. Boroproline combination therapy for cancer
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
WO2008073160A2 (en) * 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
WO2008032324A2 (en) * 2006-09-14 2008-03-20 Ramot At Tel Aviv University Ltd. Combination therapy for tumoral disease treatment
WO2009040819A2 (en) * 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. DOWN-REGULATION OF MORTALIN BY siRNA
EP2077281A1 (en) * 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
WO2009145831A1 (en) * 2008-04-02 2009-12-03 Geisinger Clinic Treatment of the idiopathic nephrotic syndrome spectrum diseases using basiliximab
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
WO2013120012A2 (en) * 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
EP3052189A4 (en) * 2013-10-03 2017-11-01 Leuvas Therapeutics Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5099069A (en) * 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
AU5361794A (en) * 1992-10-14 1994-05-09 Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5417972A (en) * 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
DE69534530T2 (de) * 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6962979B1 (en) 1995-03-14 2005-11-08 Cohesion Technologies, Inc. Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US5776746A (en) * 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ES2203916T3 (es) * 1997-09-17 2004-04-16 Ciba Specialty Chemicals Holding Inc. Aditivo antimicrobiano para detergentes.
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
JP2003509428A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
JP2004512262A (ja) * 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
US7113996B2 (en) * 2000-07-21 2006-09-26 Sandy Craig Kronenberg Method and system for secured transport and storage of data on a network
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof

Similar Documents

Publication Publication Date Title
JP2007513072A5 (https=)
US20200345854A1 (en) Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof
CN111265531B (zh) 治疗和预防移植物抗宿主病的方法
TWI793513B (zh) 對ｃｄ１２３具專一性之抗體和抗體－藥物共軛體及彼等之用途
US10654831B2 (en) Antiproliferative pyrimidine-based compounds
CN107417691B (zh) 高效的抗赘生剂和抗增生剂
Ballow et al. Immunopharmacology: immunomodulation and immunotherapy
US20180369411A1 (en) Multi-specific binding conjugate, related pharmaceutical compositions and use
CN109789143A (zh) 基于嘧啶的抗增殖剂
SA517382248B1 (ar) مركبات 4،6-ديامينو-بيريدو بيريميدين تعدل مستقبل بروتين ناقل غشائي [3،2-d]
US20120148577A1 (en) Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
WO2017185662A1 (zh) 多特异性结合偶联物、相关的药物组合物及应用
CN100477993C (zh) 用于治疗癌症的海鞘素743的组合物和用途
CN107007615A (zh) 使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法
JP2024038132A (ja) 神経内分泌腫瘍の処置の方法
WO2015198058A1 (en) Gemcitabine prodrugs
CN114340680A (zh) 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
CN107613993A (zh) 与癌症药物的联合治疗中的nk‑92细胞
JP2024531258A (ja) 微小管阻害剤に基づく抗体薬物複合体
JP2009515901A (ja) ｍＴＯＲ阻害剤投与によるがん患者の治療
DE202018006567U1 (de) Stabile, konzentrierte Radionuklidkomplexlösungen
EP4393514A1 (en) Antibody-drug conjugate conjugated via breakable linker
Micallef et al. The changing landscape of treatment options in childhood acute lymphoblastic leukaemia
US20200071420A1 (en) Antibody conjugate, and related pharmaceutical composition and application
AU2018359546A1 (en) Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy